Active substance
Methohexital
- SFDA 1
- US FDA 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BRIETAL SODIUM 500MG - 50ML VIAL | 10 mg/ml | Powder for injection · Intravenous use | 1 Vial | SAR 15.40 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| BREVITAL SODIUM | 500MG/VIAL | injectable · injection | PH HEALTH | Prescription | 27 Jun 1960 |
| METHOHEXITAL SODIUM | 500MG/VIAL | injectable · injection | ONESOURCE SPECIALTY | Prescription | 3 Oct 2024 |
| BREVITAL SODIUM | 2.5GM/VIAL; 5GM/VIAL; 200MG/VIAL | injectable · injection | PH HEALTH | Discontinued | 27 Jun 1960 |
Safety signals and safety-related labeling changes
- US FDA 27 Apr 2017 BREVITAL SODIUM — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.